A study of influence of progesterone on activity of Glycoprotein-P in vitro

Abstract

Background. Glycoprotein-P (Pgp, АВСВ1) is a transporter protein participating in pharmacokinetics of medical drugs, and also in development of resistance of tumor cells to chemotherapy.

Aim. To study the influence of progesterone on the activity of Pgp in vitro on a cell model of human small intestinal epithelium.

Materials and Methods. The work was conducted on Caco-2 cells. The activity of Pgp was evaluated by transport of fexofenadine in a special transwell-system. Concentration of fexofenadine was analyzed by HPLC method. The amount of Pgp was determined by EIA method. Four series of experiments were conducted: control – cells preincubated with clean transport medium without addition of any substances; influence of rifampicin on the activity and synthesis of Pgp in the concentration 10 µmol/l in preincubation for 3 days (induction control); influence of progesterone on the activity of Pgp in concentrations 1, 10 and 100 µmol/l in preincubation for 30 min; influence of progesterone on the activity and synthesis of Pgp in concentrations 1, 10 and 100 µmol/l in preincubation for 3 days.

Results. Progesterone in the concentrations 1 and 10 µM in incubation with cells within 30 minutes did not show any reliable influence on the activity of Pgp, however, in concentration 100 µM it reduced the activity of the transporter protein.

In incubation of Caco-2 cells with progesterone in concentrations 1, 10 and 100 µM within 3 days the activity of Pgp remained unchanged. Progesterone in concentration 100 µM in incubation within 3 days significantly increased synthesis of Pgp in enterocytes by 114.3% as compared to control, and in other used concentrations (1 and 10 µM) it produced no reliable effect.

Conclusion. In in vitro experiments on Caco-2 cells progesterone in concentration 100 µM produces a direct inhibiting effect on the activity of Pgp; however, in incubation within 3 days it increases synthesis of the transporter protein, which cancels out its inhibitory activity.

About the authors

Pelageya D. Erokhina

Ryazan State Medical University

Email: p34-66@yandex.ru
ORCID iD: 0000-0003-4802-5656

Student

Russian Federation, Ryazan

Yulia V. Abalenikhina

Ryazan State Medical University

Email: p34-66@yandex.ru
ORCID iD: 0000-0003-0427-0967
SPIN-code: 4496-9027
ResearcherId: L-8965-2018

PhD in Biological Sciences, Assistant Professor of the Department of Biological Chemistry

Russian Federation, Ryazan

Alexey V. Shchulkin

Ryazan State Medical University

Email: p34-66@yandex.ru
ORCID iD: 0000-0003-1688-0017
SPIN-code: 2754-1702
ResearcherId: N-9143-2016

MD, PhD, Assistant Professor of the Department of Pharmacology with a Course of Pharmacy of Continuing Professional Education Faculty

Russian Federation, Ryazan

Ivan V. Chernykh

Ryazan State Medical University

Email: p34-66@yandex.ru
ORCID iD: 0000-0002-5618-7607
SPIN-code: 5238-6165
ResearcherId: R-1389-2017

PhD in Biological Sciences, Head of the Department of Pharmaceutical Chemistry

Russian Federation, Ryazan

Natalia M. Popova

Ryazan State Medical University

Author for correspondence.
Email: p34-66@yandex.ru
ORCID iD: 0000-0002-5166-8372
SPIN-code: 7553-9852
ResearcherId: B-1130-2016

MD, PhD, Assistant Professor of the Department of Pharmacology with a Course of Pharmacy of Continuing Professional Education Faculty

Russian Federation, Ryazan

Alexandr A. Slepnev

Ryazan State Medical University

Email: p34-66@yandex.ru
ORCID iD: 0000-0003-0696-6554

PhD in Biological Sciences, Assistant Professor of the Department of Pharmacology with a Course of Pharmacy of Continuing Professional Education Faculty

Russian Federation, Ryazan

Elena N. Yakusheva

Ryazan State Medical University

Email: p34-66@yandex.ru
ORCID iD: 0000-0001-6887-4888
SPIN-code: 2865-3080
ResearcherId: T-6343-2017

MD, PhD, Professor, Head of the Department of Pharmacology with a Course of Pharmacy of Continuing Professional Education Faculty

Russian Federation, Ryazan

References

  1. Yakusheva EN, Shulkin AV, Popova NM, et al. Structure, functions, of P-glycoprotein and its role in rational pharmacotherapy. Reviews on Clinical Pharmacology and Drug Therapy. 2014;(2):3-11. (In Russ).
  2. Yakusheva EN, Chernykh IV, Shulkin AV, et al. Methods of identification of drugs as P-glycoprotein substrates. I.P. Pavlov Russian Medical Biological Herald. 2015;(3):49-53. (In Russ).
  3. Gatsanoga MV, Chernykh IV, Shchulkin AV, et al. The method of assessment of drugs belonging to the substrates of P-glycoprotein on female rabbits. Nauka Molodykh (Eruditio Juvenium). 2016;(3):5-10. (In Russ).
  4. Shchulkin AV, Chernykh IV, Yakusheva EN, et al. Influence of progesterone on P-glycoprotein functional activity in experiment. Khimiko-Farmatsevticheskii Zhurnal. 2018;52(7):3-8. (In Russ). doi: 10.30906/0023-1134-2018-52-7-3-8
  5. Coles LD, Lee IJ, Voulalas PJ, et al. Estradiol and progesterone-mediated regulation of P-gp in P-gp overexpressing cells (NCI-ADR-RES) and placental cells (JAR). Molecular Pharmaceutics. 2009;6(6): 1816-25. doi: 10.1021/mp900077q
  6. Fröhlich M, Albermann N, Sauer A, et al. In vitro and ex vivo evidence for modulation of P-glycoprotein activity by progestins. Biochemical Pharmacology. 2004;68(12):2409-16. doi: 10.1016/j.bcp.2004.08.026
  7. Petri N, Tannergren C, Rungstad D, et al. Transport characteristics of fexofenadine in the Caco-2 cell model. Pharmaceutical Research. 2004;21(8):1398-404. doi: 10.1023/b:pham.0000036913.90332.b1
  8. Elsby R, Surry DD., Smith VN, et al. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of P-glycoprotein to support regulatory submissions. Xenobiotica. 2008;38(7-8):1140-64. doi: 10.1080/00498250802050880
  9. Kliewer SA, Moore JT, Wade L. An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell. 1998;92(1):73-82. doi: 10.1016/s0092-8674(00)80900-9
  10. Watanabe K, Jinriki T, Sato J Effects of progesterone and norethisterone on cephalexin transport and peptide transporter PEPT1 expression in human intestinal cell line Caco-2. Biological & Pharmaceutical Bulletin. 2006;29(1):90-5. doi: 10.1248/bpb.29.90

Supplementary files

Supplementary Files
Action
1. JATS XML
2. Fig. 1. The amount of Pgp in Caco-2 line cells on exposure to progesterone (M±SD, ng/mg of protein)

Download (28KB)

Copyright (c) 2020 Erokhina P.D., Abalenikhina Y.V., Shchulkin A.V., Chernykh I.V., Popova N.M., Slepnev A.A., Yakusheva E.N.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies